COMP <GO>
NVCR vs JNJ // REVENUE GROWTH (YOY)
NovoCure Limited (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NVCR 2
— JNJ 8
▲ REVENUE GROWTH (YOY) LEADER: NVCR
LAST: $13.15 (+0.31%) • MKT CAP: $1.53B
revenue-growth
8.30%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVCR VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVCR | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.50% | 67.90% | +6.60 | NVCR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.50% | 25.50% | -53.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.96% | 2.97% | -7.93 | JNJ | /fcf-yield <GO> |
| Operating Margin | -23.50% | 34.70% | -58.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -20.80% | 28.50% | -49.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 8.30% | 6.00% | +2.30 | NVCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.54 | 5.59 | -5.05 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.8 | 62.1 | -28.30 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.53B | $662.49B | -$660.97B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVCR REV | JNJ REV | NVCR GROSS % | JNJ GROSS % | NVCR FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $655.4M | $94.19B | 74.5% | 67.9% | -$75.7M | $19.70B |
| FY 2024 | $605.2M | $88.82B | 77.3% | 69.1% | -$69.2M | $19.84B |
| FY 2023 | $509.3M | $85.16B | — | — | -$73.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVCR // BETA —
JNJ // BETA 1.08